CGM Biocompatible Materials Patent Landscape 2026
The CGM biocompatible materials field is moderately concentrated, with a small cluster of medtech and life-science firms holding nearly half of the leading filers’ combined output. Annual volume reached a peak in 2021 and has since plateaued, signaling a maturing but still active competitive space.
A tight cluster of four applicants dominates the leaderboard
The top-ranked applicant, Sanvita Medical LLC, leads with 13 patent records, followed immediately by Willow Lab Inc, Allez Health Inc, and Verily Life Sciences LLC, each with 12 patent records — an unusually flat top-tier structure where first place holds only a marginal advantage.
The top five filers account for 46% of the combined output of the hundred largest filers, indicating moderate concentration. A visible tier gap emerges after the fifth-ranked applicant, Suzhou Zhongxing Medical Technology Co., Ltd. (9 patent records), with subsequent applicants dropping to single-digit counts.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Sanvita Medical LLC | 13 | |
| 2 | Willow Lab Inc | 12 | |
| 3 | Allez Health Inc | 12 | |
| 4 | Verily Life Sciences LLC | 12 | |
| 5 | Suzhou Zhongxing Medical Technology Co., Ltd. | 9 | |
| 6 | Medtronic MiniMed Inc | 6 | |
| 7 | Cercacor Laboratories Inc | 4 | |
| 8 | The University of Hong Kong | 3 | |
| 9 | Sanvita Medical Corp | 3 | |
| 10 | TEXAS A&M UNIVERSITY | 2 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | The Board of Trustees of the University of Illinois | 2 | |
| 12 | Senseonics Inc | 2 | |
| 13 | Verily Health Inc | 2 | |
| 14 | Hodge William Gerald | 2 | |
| 15 | Arkal Medical Inc | 2 | |
| 16 | Dr. Lakshmanan S.A. | 1 | |
| 17 | SAVEETHA INST OF MEDICAL & TECH SCI | 1 | |
| 18 | Dr. Adlin Sheeba | 1 | |
| 19 | Ms. Yuganti Nitinrao Belsare | 1 | |
| 20 | Ms. Aastha Balkrushna Padawe | 1 |
The near-parity among the top four suggests that no single organization has established a decisive positional lead, leaving the competitive order susceptible to disruption from accelerating newcomers. Several applicants identified as new entrants in momentum data further underscore the unsettled nature of the rankings.
The most recent 18–24 months of filings are likely under-counted due to standard patent publication lag; apparent softness in 2024–2026 data should not be read as a trend reversal. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity peaked in 2021; technology mix is heavily weighted toward diagnostic instrumentation
The annual filing trend and IPC technology composition together reveal a field that burst into activity around 2020–2021 and has since stabilized, with an overwhelming emphasis on diagnostic and surgical device claims.
Annual filing trend
Filings were negligible before 2020, surged to a peak of 15 records in 2021, then settled into a 9–11 record range in 2022–2023. The 2024 and 2025 figures appear lower but reflect publication lag for recently filed applications; they should not be interpreted as a genuine decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & surgery) dominates the IPC mix by a wide margin, reflecting the device-centric nature of CGM biocompatibility work. Secondary branches — G01N (Material analysis & testing), H04M (Telephonic communication), A61P (Therapeutic activity), and G16H (Healthcare informatics) — each hold small but distinct shares, pointing to growing integration of sensing, connectivity, and data analytics within the technology.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
A minimally swellable biocompatible membrane and p…
The present invention relates to a biocompatible membrane, specifically to a minimally swellable biocompatible membrane and the preparation method thereof. The preparation method of the minimally swellable biocompatible membrane comprises the following steps: synthesis of a copolymer containing a skeleton and a hydrophilic group, the introduction of a… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Glucose sensors and methods of manufacturing | 293 |
| 2 | Contact lens integrated with a biosensor for the d… | 231 |
| 3 | Electrochemical glucose sensing by equilibrium glu… | 151 |
| 4 | Device, systems, methods and tools for continuous … | 113 |
| 5 | Electrochemical Sensor for a Bandage Type of Conti… | 62 |
| 6 | Real-time denoising and prediction for a continuou… | 56 |
| 7 | Contact lens integrated with a biosensor for the d… | 51 |
| 8 | Systems and methods for continuous health monitori… | 39 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the structure means for R&D investment decisions
The combination of near-peak maturity, moderate concentration, emerging academic-industry collaboration, and strong US jurisdictional dominance shapes where new entrants can realistically compete.
Field has reached maturity with annual volume plateaued near its 2021 peak
The lifecycle evidence classifies this field as Mature: annual filings have plateaued near their peak rather than continuing to climb. Teams entering now face an established prior-art landscape and will need clear differentiation — novel polymer chemistries, anti-fouling coatings, or multi-analyte sensing surfaces — to generate defensible positions.
Lifecycle: MatureFour applicants are nearly tied at the top, leaving the ranking contestable
The top five filers hold 46% of the hundred largest filers’ combined output, but the margin between first (13 patent records) and second through fourth (12 each) is minimal. This parity means no incumbent has a structurally entrenched position, and a focused filing campaign in an adjacent branch could shift the competitive order. The drop-off after rank five is more pronounced, so mid-tier entrants face a meaningful gap to close.
Moderate concentrationLimited co-filing activity; Verily Life Sciences–Verily Health pairing is the primary link
Collaboration evidence shows two co-filing relationships: Verily Life Sciences LLC with Verily Health Inc (2 joint records) and Texas A&M University with the Regents of the University of California (1 joint record). The low volume of co-filings across the corpus suggests that most innovation is being prosecuted independently, leaving academic-industry partnerships relatively underdeveloped compared to other medtech sectors.
Low co-filing densityUnited States is the dominant filing jurisdiction; Europe and PCT are secondary protection routes
The United States leads in patent-record coverage, followed by Europe (EPO) and WIPO (PCT). India is also a notable secondary market. China holds a smaller but present share, largely driven by Suzhou Zhongxing Medical Technology Co., Ltd. Organizations seeking global protection should prioritize a US-first strategy while using PCT filings to preserve optionality in European and Asian markets.
US-centric with EPO/PCT secondaryGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Verily Life Sciences LLC | Verily Health Inc | 2 |
| Texas A&M University | Regents of the University of California | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Sanvita Medical leads narrowly; Allez Health and Suzhou Zhongxing are the fastest-rising challengers
The top applicants share a heavy emphasis on A61B (diagnostic and surgical device claims), but differ in secondary technology routes — connectivity, electrochemistry, and therapeutics — that signal distinct product strategies.
Sanvita Medical LLC
Sanvita Medical LLC holds 13 patent records, the highest in the corpus. Its technology focus spans A61B 5 (Diagnosis & surgery) and a notable secondary concentration in H04M 1 (Telephonic communication) and H04W 4 (Wireless communication networks), indicating a strategy that combines biocompatible sensor design with integrated connectivity. Momentum data does not flag a recent surge, suggesting a steady, established filing cadence.
patent records: 13Allez Health Inc
Allez Health Inc holds 12 patent records and is flagged as a new entrant with 10 recent patent records, making it the most aggressive riser in the corpus. Its technology focus is concentrated entirely in A61B 5, reflecting a device-layer biocompatibility strategy without yet branching into materials chemistry or connectivity domains. Its rapid emergence warrants close monitoring as it approaches parity with the leader.
patent records: 12| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Allez Health Inc | 10 | ▲ new entrant |
| Suzhou Zhongxing Medical Technology Co., Ltd. | 5 | ▲ new entrant |
| Cercacor Laboratories Inc | 3 | ▲ new entrant |
| The University of Hong Kong | 2 | ▲ new entrant |
Under-served routes in materials chemistry and healthcare informatics
Several IPC branches adjacent to the dominant A61B core have sparse coverage relative to their technical relevance to CGM biocompatibility, pointing to areas where early filing could establish a differentiated position.
G01N · Material analysis & testing
This branch holds 15 patent records — the largest adjacent cluster outside A61B — yet represents only 8% of the total IPC record count. For CGM biocompatibility, G01N encompasses electrochemical characterization of sensor membranes, impedance spectroscopy of biofouling layers, and surface-property testing of implantable polymers. Suzhou Zhongxing Medical Technology Co., Ltd. and Cercacor Laboratories Inc are the primary filers here, but coverage remains thin. Teams with materials-characterization expertise could file in G01N to establish a sensor-material testing methodology position with relatively limited prior-art friction.
Search this in Eureka →A61K · Medicinal preparations
With only 5 patent records, A61K (Medicinal preparations) is the sparsest of the identified adjacent branches at 3% of IPC record coverage. In the CGM context, this branch covers drug-eluting biocompatible coatings and anti-inflammatory agent loading in sensor encapsulants — approaches that can extend in-vivo sensor lifetime by suppressing foreign body response. Texas A&M University is the primary academic filer in this area. The combination of low prior-art density and clear technical value for long-wear CGM sensors makes this branch a plausible entry point for groups bridging biomaterials and pharmacology.
Search this in Eureka →How leading applicants differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | A61B 5 · Diagnosis & surgery | H04M 1 · Telephonic communication | G01N 27 · Material analysis & testing | A61P 3 · Therapeutic activity of compounds | B01D 71 · Separation processes (filtration etc.) |
|---|---|---|---|---|---|
| Sanvita Medical LLC | Strong · 15 | Strong · 13 | Absent | Absent | Absent |
| Suzhou Zhongxing Medical Technology Co., Ltd. | Strong · 9 | Absent | Strong · 6 | Absent | Strong · 5 |
| Verily Life Sciences LLC | Strong · 15 | Absent | Absent | Absent | Absent |
| Willow Lab Inc | Strong · 10 | Absent | Absent | Moderate · 5 | Absent |
| Allez Health Inc | Strong · 12 | Absent | Absent | Absent | Absent |
| Cercacor Laboratories Inc | Strong · 8 | Absent | Emerging · 1 | Absent | Absent |
| Medtronic MiniMed Inc | Strong · 6 | Absent | Absent | Absent | Absent |
Frequently asked questions
The corpus covers 63 patent families. This figure represents the deduplicated family count used for overall scope; applicant rankings are reported at the patent-record level, which can exceed the family total because a family may designate multiple jurisdictions.
Sanvita Medical LLC leads with 13 patent records, followed closely by Willow Lab Inc, Allez Health Inc, and Verily Life Sciences LLC, each holding 12 patent records.
The field is classified as Mature. Annual filings peaked in 2021 at 15 records and have since plateaued in the 9–11 record range, rather than continuing to grow. The 18% recent-window growth figure reflects a multi-year cumulative increase, not an acceleration in annual filings.
The United States leads with 40 patent records, followed by Europe (EPO) with 16, India and WIPO (PCT) with 11 each, and China with 8. These counts are at the patent-record level, so a single family filing in multiple offices contributes to each jurisdiction’s total.
Momentum data identifies Allez Health Inc (10 recent patent records, flagged as a new entrant), Suzhou Zhongxing Medical Technology Co., Ltd. (5 recent records, new entrant), Cercacor Laboratories Inc (3 recent records, new entrant), and the University of Hong Kong (2 recent records, new entrant) as the most notable rising applicants.
The top-cited work covers glucose sensors and manufacturing methods (293 citations), a contact-lens-integrated biosensor for continuous monitoring (231 citations), electrochemical glucose sensing via equilibrium glucose-binding (151 citations), and a device-and-systems framework for continuous glucose monitoring (113 citations). These citations signal that foundational sensor-design and electrochemical-transduction patents carry the greatest prior-art weight in prosecution.
Ready to map your own CGM materials landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.